You are viewing the site in preview mode

Skip to main content

Table 3 Changes in total SGRQ score from baseline following dual or monotherapy of LABA and/or LAMA

From: Dual versus monotherapy with bronchodilators in GOLD group B COPD patients according to baseline FEV1 level: a patient-level pooled analysis of phase-3 randomized clinical trials

  Intervention Mean change in total score of SGRQ (SD) Treatment difference vs. dual (95% CI) p-value
GOLD III/IV Dual − 7.63 (12.09)   
LABA − 5.51 (12.76) − 2.12 (− 3.52 to − 0.72) 0.001
LAMA − 5.85 (12.84) − 1.79 (− 2.87 to − 0.70) < 0.001
GOLD I/II Dual − 7.16 (12.49)   
LABA − 6.83 (12.54) − 0.33 (− 1.83 to 1.18) 0.868
LAMA − 6.04 (12.89) − 1.12 (− 2.24 to 0.01) 0.048
  1. CI confidence interval, GOLD Global initiative for Chronic Obstructive Lung Disease, LABA long-acting beta-2 agonist, LAMA long-acting muscarinic antagonist, SD standard deviation, SGRQ St. George’s Respiratory Questionnaire
Back to article page

Respiratory Research

ISSN: 1465-993X

Contact us